Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:

•          B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
•          B-51, on radiation to the chest wall
•          Alliance trial, on lymph node dissection

Breast Cancer

Clifford A. Hudis, MD, FACP

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Breast Cancer

Jack Cuzick, PhD

Jack Cuzick, PhD, on the IBIS-I Trial

Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."

Breast Cancer

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures

Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.

Breast Cancer

Gunter von Minckwitz, MD

Gunter von Minckwitz, MD, on the Phase III ICE Trial

Gunter von Minckwitz, MD, of the University of Frankfurt, offers his thoughts on abstract S3-04, "The phase III ICE study: Adjuvant ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer."

Feb

Today In Oncology

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Jack Cuzick, PhD, on the IBIS-I Trial

Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures

Gunter von Minckwitz, MD, on the Phase III ICE Trial

Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL

Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL

Predicting Response to KRAS G12C Inhibitors in NSCLC

Rising Advanced Prostate Cancer Rates in California Follow Changes to Recommendations

Trastuzumab Pertuzumab Plus Eribulin or Taxane in Locally Advanced or Metastatic Breast Cancer